Cover Image

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a significant antibody response for some CLL patients. In this study we investigated antibody persistence after PCV7 in patients wi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vesa Lindström (Author), Janne Aittoniemi (Author), Urpu Salmenniemi (Author), Helena Käyhty (Author), Heini Huhtala (Author), Maija Itälä-Remes (Author), Marjatta Sinisalo (Author)
Format:	Book
Published:	Taylor & Francis Group, 2018-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia
by: Vesa Lindström, et al.
Published: (2019)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019)

Indirect effect and pneumococcal conjugate vaccines
by: L. Temimi
Published: (2009)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Indirect effect and pneumococcal conjugate vaccines
by: L. Temimi
Published: (2009)

Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
by: Shigeki Nakamura, et al.
Published: (2024)

Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies
by: Jacek Wysocki, et al.
Published: (2017)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

Conjugate pneumococcal vaccines: Need and choice in India
by: Akash Malik, et al.
Published: (2013)

Herd protection induced by pneumococcal conjugate vaccine
by: Keith P Klugman
Published: (2014)

Incidence of pneumonia is not reduced by pneumococcal conjugate vaccine
by: Sona Chowdhary, et al.
Published: (2008)

Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age
by: Raul E. Isturiz, et al.
Published: (2018)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

Chronic Lymphocytic Leukemia
Published: (2012)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023)

Burden of pneumococcal disease in children in Cuba before the introduction of a novel pneumococcal conjugate vaccine
by: Nivaldo Linares-Pérez, et al.
Published: (2019)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines
by: Echániz-Avilés Irma Gabriela, et al.
Published: (2001)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

CONJUGATED PNEUMOCOCCAL VACCINE FOR IMMUNIZATION OF CHILDREN - WHO RECOMMENDATIONS
by: L.S. Namazova
Published: (2007)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

CONJUGATED PNEUMOCOCCAL VACCINE FOR IMMUNIZATION OF CHILDREN - WHO RECOMMENDATIONS
by: L.S. Namazova
Published: (2007)

Pneumococcal conjugate vaccines: choice of schedule and product development
by: Jin Lee
Published: (2020)

Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines
by: Hyunju Lee, et al.
Published: (2014)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: An interrupted time-series analysis
by: Diana C. Caceres, et al.
Published: (2018)

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey
by: Ayşe Büyükcam, et al.
Published: (2017)

Immunogenetics of chronic lymphocytic leukemia
by: Nikhil Patkar, et al.
Published: (2017)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
by: Godwin Oligbu
Published: (2020)

Pneumococcal conjugate vaccine is efficacious and effective in reducing the burden of pneumonia
by: Shabir A Madhi, et al.
Published: (2008)

Pneumococcal conjugate vaccine and changing epidemiology of childhood bacterial meningitis
by: Shabir A. Madhi
Published: (2015)

Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam
by: Olivier Le Polain De Waroux, et al.
Published: (2018)